Genetic Polymorphisms Associated with Vincristine Pharmacokinetics and Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients.
DNA
area under the curve
cancer
children
maximum concentration
neurotoxicity
single-nucleotide polymorphism
toxicity
vincristine
whole-exome sequencing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
received:
13
05
2022
revised:
11
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Vincristine (VCR) is an important component of curative chemotherapy for many childhood cancers. Its main side effect is VCR-induced peripheral neuropathy (VIPN), a dose limiting toxicity. Some children are more susceptible to VIPN, which is at least partially dependent on genetic factors and pharmacokinetics (PK). In this study, we identify and replicate genetic variants associated with VCR PK and VIPN. Patient samples from a randomized clinical trial studying the effect of administration duration of VCR on VIPN in 90 patients were used. PK sampling was conducted on between one and five occasions at multiple time points. A linear two-compartment model with first-order elimination was used, and targeted next-generation DNA sequencing was performed. Genotype-trait associations were analyzed using mixed-effect models or logistic regression analysis for repeated measures, or Poisson regression analysis in which the highest VIPN score per patient was included. Nine single-nucleotide polymorphisms (SNPs) in seven genes (NDRG1, GARS, FIG4, FGD4, SEPTIN9, CEP72, and ETAA1) were associated with VIPN. Furthermore, three SNPs in three genes (MTNR1B, RAB7A and SNU13) were associated with PK of VCR. In conclusion, PK of VCR and VIPN are influenced by SNPs; upfront identification of those that lead to an altered susceptibility to VIPN or VCR exposure could help individualize VCR treatment.
Identifiants
pubmed: 35884569
pii: cancers14143510
doi: 10.3390/cancers14143510
pmc: PMC9321338
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Netherlands Organization for Health and Development (program Proper Use of Medication)
ID : 836021006
Organisme : Belgian Health Care Knowledge Centre
ID : 16015
Organisme : Fulbright, the Netherlands
Organisme : Cancer Center Amsterdam
Organisme : René Vogels Foundation
Organisme : Ter Meulen Grant by the Academy Medical Sciences Fund
Références
J Biol Chem. 2021 Jan-Jun;296:100455
pubmed: 33636182
J Pediatr. 1994 Oct;125(4):642-9
pubmed: 7931891
J Neurol Sci. 2019 Jul 15;402:156-161
pubmed: 31152969
Cancers (Basel). 2022 Jan 26;14(3):
pubmed: 35158880
Cell. 2019 Jan 24;176(3):535-548.e24
pubmed: 30661751
Cancer Med. 2021 Nov;10(22):8172-8181
pubmed: 34725942
Am J Clin Nutr. 2022 Feb 9;115(2):388-396
pubmed: 34669935
Brain. 2011 Jun;134(Pt 6):1839-52
pubmed: 21576112
Int J Mol Sci. 2021 Jul 22;22(15):
pubmed: 34360602
Pediatr Blood Cancer. 2011 Mar;56(3):361-7
pubmed: 21225912
Br J Haematol. 2008 Aug;142(4):616-21
pubmed: 18537965
Future Sci OA. 2020 May 27;6(7):FSO582
pubmed: 32802391
Child Neurol Open. 2016 Sep 19;3:2329048X16668970
pubmed: 28503616
Neuromuscul Disord. 2021 Jan;31(1):56-68
pubmed: 33334662
Pharmacogenet Genomics. 2016 Feb;26(2):100-2
pubmed: 26618658
Mol Genet Genomic Med. 2014 Nov;2(6):522-9
pubmed: 25614874
Carcinogenesis. 2008 Jan;29(1):2-8
pubmed: 17916902
Lancet Oncol. 2010 Nov;11(11):1057-65
pubmed: 20864405
Lancet Haematol. 2020 May;7(5):e408-e417
pubmed: 32359452
World J Gastroenterol. 2021 Sep 14;27(34):5737-5752
pubmed: 34629798
Curr Biol. 2016 Dec 19;26(24):3257-3268
pubmed: 27818175
Br J Haematol. 2003 Jul;122(2):240-4
pubmed: 12846892
Cancers (Basel). 2020 Dec 12;12(12):
pubmed: 33322788
Ann Hum Genet. 2015 Nov;79(6):460-9
pubmed: 26400421
Support Care Cancer. 2014 Feb;22(2):359-66
pubmed: 24072474
J Cell Biol. 2013 Dec 23;203(6):895-905
pubmed: 24344182
Crit Rev Oncol Hematol. 2017 Jun;114:114-130
pubmed: 28477739
Clin Pharmacol Ther. 2019 Feb;105(2):402-410
pubmed: 29999516
Cancer Chemother Pharmacol. 1988;22(3):271-4
pubmed: 3044635
Cell Mol Life Sci. 2021 Jan;78(1):351-372
pubmed: 32280996
Case Rep Pediatr. 2018 Jan 30;2018:8516285
pubmed: 29527379
Pharmacogenomics. 2016 May;17(7):731-41
pubmed: 27180762
Chem Sci. 2019 Mar 11;10(15):4272-4281
pubmed: 31015952
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Orphanet J Rare Dis. 2013 Jul 12;8:104
pubmed: 23844677
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Clin Pharmacol Ther. 2017 Mar;101(3):391-395
pubmed: 27618250
JAMA. 2015 Feb 24;313(8):815-23
pubmed: 25710658
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28139029
Cancer. 2004 Jun 15;100(12):2637-43
pubmed: 15197807
Blood. 2007 May 15;109(10):4151-7
pubmed: 17264302
J Am Chem Soc. 2022 Jan 12;144(1):454-462
pubmed: 34978433
J Pediatr Oncol Nurs. 2018 Jul/Aug;35(4):267-275
pubmed: 29566596
Support Care Cancer. 2013 Mar;21(3):847-56
pubmed: 22993026
J Paediatr Child Health. 2011 Dec;47(12):875-82
pubmed: 21658147
Pharmacogenet Genomics. 2018 Aug;28(8):189-195
pubmed: 30119132
Clin Transl Sci. 2021 Jul;14(4):1490-1504
pubmed: 33742760
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635465
Pediatr Blood Cancer. 2018 Mar;65(3):
pubmed: 29115708
Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87
pubmed: 10226730
Pancreas. 2019 Nov/Dec;48(10):1307-1311
pubmed: 31688594
Int J Hematol. 2020 May;111(5):686-691
pubmed: 31993939
Biochem J. 2000 Sep 1;350 Pt 2:337-52
pubmed: 10947947